Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 7685 results

  1. Digital support for children and young people with eating disorders:early value assessment

    Awaiting development [GID-HTE10058] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  2. Cladribine for treating relapsing multiple sclerosis [ID6263]

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  3. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]

    In development [GID-HST10059] Expected publication date: 05 March 2025

    Highly specialised technologies guidance
    In development

  4. Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults

    In development [GID-IPG10362] Expected publication date: 09 January 2025

    Interventional procedures guidance
    In development

  5. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  6. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  7. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

    Quality standard
    In development

  8. Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

    In development [GID-TA11496] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  9. Digital platforms to support cardiac rehabilitation

    Awaiting development [GID-HTE10060] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  10. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development [GID-TA11379] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  11. Digital technologies to support self-management of COPD: early value assessment

    In development [GID-HTE10030] Expected publication date: 19 December 2024

    Health technology evaluations
    In development

  12. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462

    In development [GID-TA11602] Expected publication date: 11 September 2025

    Technology appraisal guidance
    In development

  13. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment: draft guidance

    We are listening to your views on this Health technology evaluation. Comments close 17 December 2024.

    Health technology evaluation
    In consultation

  14. Non-alcoholic fatty liver disease (NAFLD): assessment and management

    In development [GID-NG10434] Expected publication date: TBC

    NICE guideline
    In development

  15. Intrapartum Care - maternal hyponatremia

    In development [GID-NG10431] Expected publication date: 26 March 2025

    NICE guideline
    In development